Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease [AD]) in frontotemporal dementia patients after a one-year treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nantes University Hospital
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Patients with FTD based on the criteria defined by the Lund and Manchester groups' consensus statement (revised in 1998), whose disease has been progressing during the last year.

• MMSE score of 19 or higher

• Men and women aged 45 to 75 years

• Without speech, visuospatial, or episodic memory impairments

Exclusion Criteria:

• Age > 76 years

• Illiterate or misunderstanding patients

• Patients with cancer, heart disease, lung disease, kidney disease (creatinine > 200 mg/dL), or epilepsy